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Turning mirror-image
oligonucleotides into drugs: the
evolution of Spiegelmer1
therapeutics§
Axel Vater and Sven Klussmann
NOXXON Pharma AG, Max-Dohrn-Strasse 8-10, 10589 Berlin, Germany
Spiegelmers are synthetic target-binding oligonucleotides built from non-natural L-nucleotides. Like
aptamers, Spiegelmers fold into distinct shapes that bind the targets with high affinity and selectivity.
Furthermore, the mirror-image configuration confers plasma stability and immunological passivity.
Various Spiegelmers against pharmacologically attractive targets were shown to be efficacious in
animal models. Three Spiegelmer candidates: emapticap pegol (NOX-E36; anti-CCL2), olaptesed pegol
(NOX-A12; anti-CXCL12) and lexaptepid pegol (NOX-H94; anti-hepcidin), underwent regulatory safety
studies, demonstrated good safety profiles in healthy volunteers and were taken into Phase IIa studies in
patients. Proof-of-concept for emapticap pegol has recently been demonstrated in diabetic nephropathy
patients. Furthermore, promising interim Phase IIa data of olaptesed pegol and lexapteptid pegol also
suggest efficacy in the respective patient populations.Introduction
Single-stranded nucleic acids can adopt 3D structures determined
by their nucleotide sequence. This is comparable to proteins where
the 3D structure is dependent on their amino acid sequence.
Employing in vitro selection techniques, functional oligonucleo-
tide sequences with target-binding or even enzymatic activity can
be identified from combinatorial oligonucleotide libraries [1–3]
and the oligonucleotides are referred to as aptamers or ribozymes,
respectively. The screening technology that is employed to iden-
tify aptamers has been described as systematic evolution of ligands
by exponential enrichment (SELEX). Within the SELEX process,
oligonucleotide libraries consisting of random sequence regions
and fixed-flanking primer-binding sites are subjected to consecu-
tive rounds of selection and amplification. During the selection
step, target-binding oligonucleotides are partitioned from non-
binding sequences and the binding sequences are isolated and
then enzymatically amplified (e.g. by polymerase chain reaction).
Structural motifs commonly found in aptamers comprise not only
classical helices with Watson–Crick base pairing but also internal
bulges, hairpin loops, G-quartets and pseudo-knots.§ Spiegelmer is a registered trademark of NOXXON Pharma AG.
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http://dx.doi.org/10.1016/j.drudis.2014.09.004 Numerous aptamers have been identified against targets as
small as nickel (58.7 Da) [4], as large as complement C5
(190 kDa) [5] and even surface molecules on whole cells [6].
Aptamers have been shown to be useful as a chemical alternative
to antibodies in a number of applications. These include diagnos-
tics that employ ELISA-type oligonucleotide ligand assays (ELO-
NAs or OLAs) or biosensors, purification processes with aptamer-
loaded affinity resins, delivery vehicles for therapeutic siRNAs and
therapeutics that can disrupt protein–protein interactions [7].
Chemical modification of aptamers
If RNA- or DNA-based aptamers are intended to be used in a
biological environment, and particularly for therapeutic use, they
have to be stabilized against cleavage by endo- and exo-nucleases.
Because these nucleases are abundant in biological fluids, several
modifications of nucleotides were introduced that protect the
vulnerable 20-position of the ribose-phosphate backbone against
endonucleases (20-fluoro, 20-amino, 20-O-methyl) and the terminal
nucleotides against exonucleases. Such modifications have led to
increased plasma stability in vitro [8]. However, the aptamers
usually cannot be completely modified and thereby protected
without loss of binding affinity, therefore some degree of biologi-
cal instability remains.cense (http://creativecommons.org/licenses/by/3.0/).
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yDerived from the German word Spiegel: mirror, and the Greek word meros:
part, which is also used in the words aptamer and polymer.
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NBesides the modifications mentioned above, aptamers that are
to be used therapeutically are commonly conjugated to a high
molecular weight polyethylene glycol (PEG) moiety (40 kDa), this
increases their residence time in the bloodstream by decreasing
their elimination from plasma by glomerular filtration [8]. In
contrast to the typical random PEGylation of most antibody
fragments and several therapeutic proteins, PEG can be conjugated
site-specifically to oligonucleotides and aptamers. This is achieved
by introducing a linker with an appropriate functional group at the
desired position during solid-phase synthesis. As a result, the
selective PEGylation of aptamers typically preserves the desired
activity in contrast to many proteins that show decreased activity
owing to a random reaction at many different sites.
Conventional aptamers in clinical development
The use of aptamers for therapeutic applications became possible
when ways of stabilizing nucleic acids against nucleolytic attack in
biological fluids were successfully implemented [9]. In 2004, anti-
vascular endothelial growth factor (VEGF)-A165-aptamer pegapta-
nib sodium (Macugen1, Pfizer) for the treatment of the neovas-
cular form of age-related macular degeneration (AMD) became the
first, and to-date only, aptamer drug to gain FDA approval [10].
Although Macugen1 required injections into the eyeball every six
weeks, it was the first treatment for AMD that could effectively
slow down progression. It has now been superseded in the market
by the broader-acting VEGF-A-targeting therapeutics bevacizumab
(Avastin1, Chugai/Genentech/Roche: antibody), ranibizumab
(Lucentis1, Genentech/Novartis: Fab fragment) and aflibercept
(Eylea1, Bayer/Regeneron: VEGF-trap), which also require intravi-
treal injections [11].
The original anti-VEGF-A aptamer (t44-OMe) is stabilized by 20-
deoxy-20-fluoro-pyrimidine and by changing all but two purine
nucleotides into 20-O-methylpurines [12]. Additionally, pegapta-
nib (NX1838, EYE001) carries a 40 kDa Y-shaped (branched) PEG
to improve pharmacokinetic (PK) properties further and an
inverted dT at its 30 end as a shield against 30-exonucleases [13].
Ophthotech is developing E10030, an anti-platelet-derived
growth factor (PDGF)-BB aptamer (Fovista1) also known as
ARC127 that is currently in Phase III clinical studies for the
treatment of neovascular (wet) AMD in combination with rani-
bizumab (clinicaltrials.gov: NCT01940900). The sequence, a
36mer published in 1996 [14], originated from a DNA library
and was only modified with a 30-30-linked thymidine nucleotide
to reduce exonuclease attacks. Further truncation and post-SELEX
modifications (20-deoxy-20-fluoro-pyrimidines, 20-O-methyl-pur-
ines, internal hexyl-linkers, all wherever possible) to improve
nuclease resistance resulted in a 32mer that was later named
ARC126 and ARC127 when PEGylated at the 50 terminus [15].
E10030 is administered by intravitreal injection.
A second therapeutic candidate in Ophthotech’s clinical pipe-
line is the C5-binding aptamer ARC-1905 (Zimura1). The 38mer
aptamer sequence was originally identified from a 20-deoxy-20-
fluoro-pyrimidine-modified library and all but three purines could
be exchanged for 20-O-methyl purine nucleotides [5]. For in vivo
applications, an inverted thymidine and a 40 kDa PEG moiety
were added to the 30 and 50 end, respectively [16]. ARC1905 has
completed Phase I/IIa studies in combination with anti-VEGF
treatments.148 www.drugdiscoverytoday.comThe only aptamer destined for systemic use and currently active
in clinical development is pegnivacogin (RB006, Regado Bios-
ciences), a coagulation factor-IXa-neutralizing aptamer. It was
originally identified as a 34-nucleotide-long sequence with 20-
deoxy-20-fluoro-modified pyrimidines and an inverted T as 30
cap [17]. For further development it was trimmed to 31 nucleo-
tides, all but one purine was exchanged to the corresponding
20-O-methyl-nucleotides, 20-deoxy-20-fluoro-pyrimidines were ex-
changed for the respective 20-O-methyl nucleotides where possible
and a 40 kDa PEG moiety was conjugated to the 50 end [18]. It is
being co-developed with its antidote, anivamersen (RB007), an all-
20-methoxy 15-nucleotide-long reverse complementary oligonu-
cleotide that inactivates the target-binding property of the apta-
mer by unfolding its active structure and forcing it into a double-
helix with the antidote. The two-component anticoagulation
system pegnivacogin/anivamersen (Revolixys1 kit) has been un-
dergoing Phase III studies in the setting of percutaneous coronary
intervention (where it is administered intravenously) and Phase I
studies for venous thrombosis (where it is administered via the
subcutaneous route).
Mirror-image (L-)aptamers are plasma stable
An alternative way of making therapeutic aptamers is the use of
mirror-image RNA or DNA that is not recognized by the ubiquitous
plasma nucleases [19]. In a mirror-image aptamer, also known as a
Spiegelmer,y all chirality centers that are only located in the
(deoxy)ribose sugars of the nucleotide, are mirror-inverted [20].
These L-(deoxy)ribose-based nucleotides do not occur in nature
and are perfect mirror-images of the corresponding, natural D-
nucleotides. By analogy, L-aptamers (Spiegelmers), which are
chains of L-nucleotides, are perfect mirror images of their D-apta-
mer counterparts of the same sequence. Thus, in the only available
crystal structure of an L-oligonucleotide, a left-turning helix in-
stead of the typical right-turn helix is observed [21]. Because
naturally occurring enzymes are stereoselective, Spiegelmers –
unlike aptamers – enjoy a native biostability. As mentioned above,
also aptamers can be stabilized against nucleolytic attacks; how-
ever, the stabilization process can be cumbersome because vulner-
able nucleotides need to be exchanged for modified nucleotides.
This is usually not possible for all positions because the overall
(target-)binding conformation needs to be maintained.
Generation of Spiegelmers
Ideally, Spiegelmers would be directly selected to bind to a target of
choice. However, such a method would require enzymes that rec-
ognize mirror-image (oligo)nucleotides and catalyze the respective
amplification processes such as PCR, and for RNA also transcription/
reverse transcription. Additionally, sequencing of the enriched
library after the final round of selection currently depends on
cloning in bacteria (Escherichia coli) and further polymerase chain
reactions, methods that would be difficult to adapt for mirror-image
libraries. Therefore, the Spiegelmer identification process relies on
the generation of conventional, D-configured aptamers against a
synthetic selection target that is the mirror-image of the biological
Drug Discovery Today  Volume 20, Number 1  January 2015 REVIEWS
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Natural target
Spiegelmer (L-RNA)
binding to the natural target
FIGURE 1
Illustration showing the generation of an RNA-Spiegelmer against the chemokine CXCL12. As a first step, a mirror image of the natural target is synthesized. RNA
oligonucleotides (aptamers) binding to the mirror-image selection target are then identified by in vitro selection from a synthetic oligoribonucleotide library in the
natural D-configuration. The natural D-configuration is required because stereoselective enzymes are used for amplification, cloning and sequencing of bound
sequences. Identified sequences are finally synthesized using enantiomeric (L-)ribonucleotides. The resulting Spiegelmer binds to the natural target. Artwork by
Christian Mihm.
R
ev
ie
w
s
 P
O
S
T
S
C
R
E
E
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produced in its respective mirror-image configuration from non-
natural L-nucleotides. Following the rules of symmetry, the resulting
L-aptamers (Spiegelmers) bind to the natural target with the same
affinity as the D-aptamers bind to the mirror-image selection target
[20]. The identification of RNA-Spiegelmers is schematically repre-
sented in Fig. 1.
The SELEX process generally consists of 10–20 rounds of selec-
tion (under physiological conditions, i.e. pH, ions and tempera-
ture) and amplification. To separate binding from nonbinding
sequences, the target is often biotinylated so that complexes
can be captured using streptavidin- or neutravidin-coated beads
which can then be separated from the solution by filtration. By
adjusting target and oligonucleotide concentrations, wash
volumes and competing, unspecific oligonucleotides, an efficient
depletion of nonbinding or weakly binding oligonucleotides can
be achieved [1,22].
An essential step in developing a commercially viable aptamer is
the efficient truncation of the resulting sequences to the minimal
binding motif [22]. Each nucleotide that is saved reduces
manufacturing costs because of less raw material consumption,
increasing yields in solid phase synthesis and more-efficient HPLC
purification owing to better separation of full-length product from
truncated variants. The length of a final Spiegelmer candidate
typically is within the range of 30–50 nucleotides. L-Aptamers
against almost 20 targets have been published to date. Although
small targets such as adenosine [20] and arginine [68] were used in
the initial proof-of-concept studies that supported the generalprinciple of identifying Spiegelmer-based oligonucleotides; later
targets with more-important pharmacological relevance have also
been pursued and used in subsequent programs (Table 1).
As anticipated, affinity and selectivity of Spiegelmers for their
respective targets seem to be comparable to conventional D-con-
figured aptamers. A high selectivity is definitely desirable for in vivo
applications to reduce unwanted side-effects; however, it can also
impose difficulties in animal studies whenever the target of inter-
est is not recognized by the candidate aptamer because of low
species homology. This difficulty was first encountered in the anti-
monocyte chemoattractant protein (MCP)-1 program [23]. At first,
the Spiegelmer NOX-E36 was identified against human MCP-1, but
it did not bind to murine MCP-1 that only shares 55% homology
to the human protein. As a consequence, an additional drug
discovery process was started to identify a rodent-specific anti-
MCP-1 Spiegelmer, called mNOX-E36. The rodent anti-MCP-1
served as a surrogate for the preclinical evaluation of Spiegel-
mer-mediated MCP-1 inhibition in the respective efficacy models
but it was also used for GLP toxicity studies in mice. By contrast,
the target of NOX-A12, the second Spiegelmer that entered clinical
trials, is the well-conserved chemokine stromal-cell-derived factor
(SDF)-1 (97% homology between murine and human protein).
NOX-A12 is cross-reactive to the murine, rat and cynomolgus
monkey protein, thereby enabling preclinical research and devel-
opment without the need for a surrogate.
The third clinical L-aptamer, the anti-hepcidin Spiegelmer
NOX-H94, is selective for the human and cynomolgus monkey
target protein but, despite a 75% homology to murine hepcidin,www.drugdiscoverytoday.com 149
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TABLE 1
Overview of published L-aptamers grouped by development stage.
Target Designation Kd [nM] IC50 [nM] Animal model efficacy Clinical efficacy
Monocyte chemoattractant
peptide MCP-1/CCL2
NOX-E36/
emapticap
pegol
1.05
(unpublished)
0.5 [23] NOX-E36 is human- and cynomolgus-monkey-
specific; efficacy studies were done in mouse
with mNOX-E36 (see below)
Placebo-controlled Phase I, SAD and four-week MAD
completed, PD-effect: reduction of CCR2+ monocytes in
peripheral blood [24]
Double-blind, placebo-controlled Phase IIa trial in diabetic
patients with albuminuria (three months treatment, three
months follow-up): reductions in albuminuria and improved
glycemic control (HbA1c); renoprotective effect maintained
in absence of drug (three months) [25]
Murine MCP-1 (CCL2) mNOX-E36 0.16 [26] 3 [26] Lupus nephritis in MRLlpr/lpr mice [26,27]
Diabetic nephropathy in uninephrectomized
diabetic (db/db) mice [28,29]
Liver inflammation and steatohepatitis (CCl4-,
bile-duct ligation or methionine-choline-
deficient diet-induced hepatic injury) [30,31]
Acceleration of liver fibrosis regression [32]
Rodent models of chronic obstructive
pulmonary disease (LPS-induced neutrophilia or
tobacco-smoke-induced) [33]
Pulmonary arterial hypertension in rat
(monocrotaline-induced) and mouse (chronic-
hypoxia-induced) [34]
Stromal-cell-derived factor-1
(SDF-1/CXCL12)
NOX-A12/
olaptesed
pegol
0.20 [35] 0.20 [35] Hematopoietic stem cell/WBC mobilization in
mice and/or monkeys [35]
Reduced MM tumor burden in SCID mice in
combination with bortezomib [36]
Reduced homing of primary human CLL cells to
bone marrow and increased mobilization to
peripheral blood of CLL-like cells in mice [37]
Rat glioblastoma [38]
Pulmonary arterial hypertension
(monocrotaline-induced) in rats [39]
Diabetic nephropathy in db/db mice (T2DM
model) [29,40]
Improved pancreatic islet engraftment after
transplantation [41]
Phase I, SAD: hematopoietic stem cell and WBC mobilization
[35]
Phase IIa for chemosensitization in MM (with VD) [42] and
CLL (with BR) [43] ongoing
Hepcidin NOX-H94/
lexaptepid
pegol
0.65 [44] 20 [44] IL-6-induced anemia in cynomolgus monkeys
[44]
Phase I: dose-dependent increases in serum iron in healthy
volunteers [45]
PK/PD study: inhibition of LPS-induced serum iron decrease
[46]
Phase IIa in anemia of cancer ongoing
TAR (viral RNA) L-6-4t 100 [47] –
Complement C5a NOX-D19 1.40 [48] 1.90 [48] Improved vascular integrity and reduced airway
remodeling in a murine model for lung
transplantation [49]
NOX-D20 0.30 [48] 0.28 [48] Improved survival, organ function, reduced
capillary leakage and inflammatory cytokines in
a murine model of polymicrobial sepsis [48]
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Glucagon NOX-G15 3.0 [50] 3.07 [50] Murine models of type 1 and type 2 diabetes
mellitus [50]
Sphingosine-1-phosphate
(signaling lipid)
NOX-S93 4.3 [51] 5.5 [51] Reduction of rhabdomyosarcoma cell seeding to
bone marrow (metastasis model) [52]
High mobility group protein
A1a/b (HMGA1a/b)
NOX-A50 7.1 [53] 15.4 [53] Reduction of xenograft tumor growth by
Spiegelmer-PEG-polyethyleneimine polyplexes
(s.c. implanted pancreatic cancer cell line) [53]
Amylin NOX-A42 19 [54] Inhibition of amylinergic responses in the rat
brain, for example, treatment of cancer-induced
hyperamylinemia [55]
Rat calcitonin gene-related
peptide (CGRP)
NOX-C89 32 [54] 4 [54] Rat migraine model [56]
Ghrelin (acylated) NOX-B11 35 [57] 5 [57] Inhibition of growth hormone release induced
by exogenous ghrelin in rats [57]
NOX-B11-2 35 [58] 5 [58] Amelioration of diet-induced obesity inmice[58];
decrease of calorie utilization; inhibition of body
weight recuperation after fasting [59]
NOX-B11-3 4 [60] 4.5 [61]
Gonadotropin-releasing
hormone (GnRH)
NOX 1257 20 [62] 20 [62] Inhibition of GnRH-induced luteinizing hormone
overexpression in rats following castration [62]
Substance P SUP-A-004 40 [63] 45 [63]
Nociceptin NOX 2149 110 [64] 10 000 [64]
Staphylococcal enterotoxin
B (SEB)
B12b10_65 420 [65]
Vasopressin ‘Williams et al.’ 1200 [66] 4000 [66]
NOX-F37 1.3 [67] 1 [67] Aquaretic diuresis (no loss of electrolytes) in rats
[67]
Arginine R16-c 129 000 [68]
Adenosine A42d 1800 [20]
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was demonstrated in a cynomolgus monkey model. In the absence
of a second relevant species, the preclinical, GLP-compliant devel-
opment was only done in monkeys.
In the context of selectivity, an unexpected finding occurred in
the C5a program. While selecting oligonucleotides binding to
murine C5a, NOX-D19 and its followers NOX-D20 and NOX-
D21 were identified as recognizing the intended mouse C5a as
well as human C5a but not monkey or rat C5a. The alignment of
the involved sequences revealed two out of 74 amino acids that are
conserved in the species mouse and human but are different in rat
and cynomolgus monkey. Thus, one or both amino acids must be
responsible for this unusual specificity phenomenon. The murine
target had initially been picked in to enable preclinical research for
existing human-C5a-specific Spiegelmers [69].
The basis of every drug discovery approach is the initial prepa-
ration of a target molecule. The prerequisite for a Spiegelmer drug
discovery process (Fig. 1) is to get access to the non-natural
enantiomer of the intended target (in case the target is chiral)
thus requiring a synthetic chemical process. Because the most
interesting pharmacological targets are polypeptide-based, meth-
ods of solid-phase peptide synthesis and ligation techniques are
usually employed to prepare mirror-image polypeptides consisting
of D-amino acids. Currently, commercial protein synthesis can
provide polypeptide chains of approximately 100–150 amino acids
in length. However, in academic projects sometimes even consid-
erably longer proteins are prepared chemically; the longest fully
synthetic protein reported to date is the 312-residue E. coli
4-hydroxy-tetrahydrodipiconilate synthase (EC 4.3.3.7) (DapA)
[70]. Taking into consideration that usually only epitopes of
polypeptides and proteins are recognized, also smaller domains
of larger proteins can serve equally well as selection targets. This
approach, already established for the generation of antibodies [71],
was also demonstrated for Spiegelmers. Examples include the
selection against a 25-amino-acid-long peptide from Staphylococcus
enterotoxin B (SEB) (239 amino acids) and against a 21-amino-
acid-long central DNA-binding domain of the high mobility group
protein A1 architectural transcription factors HMGA1a (107 ami-
no acids) and HMGA1b (96 amino acids) [53,65].
Pharmacokinetics
Owing to their low molecular weight, unmodified oligonucleo-
tides including Spiegelmers are rapidly cleared by the kidneys [72].
The renal clearance, however, can be slowed down by attaching
moieties such as PEG that increase the hydrodynamic radius of the
oligonucleotide. By this means, the half-life of an oligonucleotide
can be tuned up to a limit that is set by a combination of biological
stability and residual plasma clearance (e.g. uptake by phagocytes
and residual renal elimination) [62]. To date, 40 kDa PEG is the
only modification for aptamers that has been tested in clinical
trials and it was this form of PEG that was approved as part of
pegaptanib sodium (Macugen1). PEG of this size is also an integral
part of the anti-tumor necrosis factor (TNF)a antibody fragment
certolizumab pegol (Cimzia1, UCB), a systemic treatment for
rheumatoid arthritis and other autoimmune conditions that has
been marketed since 2007. Likewise, all Spiegelmers that have
been tested for in vivo efficacy are modified with a Y-shaped
40 kDa PEG moiety.152 www.drugdiscoverytoday.comThree clinical Spiegelmer programs revealed nearly dose-linear
PK profiles with half-lives in humans of 50 h for NOX-E36, 40 h for
NOX-A12 and 23 h for NOX-H94 [24,35,73]. For reasons of safety,
the Spiegelmers were generally first administered intravenously as
a 15 or 30 min infusion before switching to a slow bolus injection
in the majority of the later clinical studies. NOX-E36 and NOX-
H94 have also been injected subcutaneously with a reported
bioavailability of approximately 50% for NOX-E36 [24].
Efficacy in preclinical disease models
The published models in which Spiegelmers have been tested
cover a wide range of chronic diseases (e.g. inflammatory disease,
cancer and anemia) as well as acute or subacute diseases. Disease
models include stem cell mobilization, glucose tolerance tests in
type 1 and 2 diabetes, septic shock as well as chronic studies, such
as glioblastoma, tumor xenograft, lupus nephritis and diabetic
nephropathy. An overview is presented in Table 1.
Manufacturing
The Spiegelmer oligonucleotides are synthesized by solid-phase
chemistry on controlled pore glass (CPG) support employing tert-
butyl-dimethylsilyl (TBDMS) protected phosphoramidites of
L-nucleotides [74]. As L-nucleotides do not exist in nature they have
to be synthesized chemically from precursors. The most convenient
starting material is L-arabinose, which can be isolated from sugar
beet or wood. L-Arabinose is first epimerized catalytically to L-ribose,
L-ribose is then per-acylated and, finally, the individual nucleobases
are attached using the Vorbru¨ggen nucleosidation reaction [75]. The
resulting L-nucleosides are then converted into fully protected (20-
TBDMS) phosphoramidites following processes that are also well
established for the enantiomeric counterparts in the D-configura-
tion. For in vivo applications, the mirror-image oligonucleotides are
usually PEGylated. For PEGylation, an aminohexyl linker is added to
either end of the oligonucleotide and the PEG (NHS-ester) is conju-
gated to the primary amine of the linker mannerin a site-directed
manner [74]. After lyophilization the Spiegelmer drug substance is
reconstituted in a formulation solution and then sterile filtered to
yield the bulk investigational medicinal product (IMP) for parenter-
al injection.
Spiegelmer-specific quality control measures include purity
(HPLC), mass identity (mass spectrometry) and sequence identity
(sequencing) [76] of the unconjugated intermediate Spiegelmer, as
well as potency using cell-based assays or, if no reliable cell-based
assay can be established, a binding assay. Furthermore, particulate
matter, sterility and endotoxin content in the IMP are monitored.
Batches of up to 200 g PEGylated Spiegelmer (mass based on the
molecular weight of the oligonucleotide part) have been manu-
factured by contract manufacturing organizations (CMOs) operat-
ing under GMP. Scale-up is considered straightforward and will
lead to further reductions of cost of goods. The shelf-life of the
drug substance and drug product at storage temperatures of 20 8C
or 2–8 8C is currently three years (unpublished data) but is likely to
increase further as more stability data become available.
Generic names of Spiegelmer drugs
Until recently, no common stem had been established in the
international nonproprietary nomenclature for aptamer-based
drugs. Precedents were pegaptanib, pegnivacogin or egaptivon
Drug Discovery Today  Volume 20, Number 1  January 2015 REVIEWS
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aptamers and mirror-image aptamers alike, whereby the stem is to
be located as an infix in the middle of the name [77]. Following the
new rule, the names olaptesed pegol (NOX-A12), emapticap pegol
(NOX-E36) and lexaptepid pegol (NOX-H94) were formed, where-
by one can recognize slight but scrambled reference to their targets
SDF-1, MCP-1 and liver-expressed antibacterial peptide (another
name for hepcidin), respectively.
Proof of mechanism in humans and ongoing clinical
trials
NOX-A12: olaptesed pegol
SDF-1 is a major retention factor for hematopoietic cells in the
bone marrow. NOX-A12 blocks and detaches SDF-1 from the
surface of bone marrow stromal cells (BMSCs), thereby neutraliz-
ing the local chemokine gradient in a dual way [78]. As a result,
NOX-A12 mobilizes hematopoietic stem cells (CD34-positive cells,
colony-forming cells of the different lineages) as well as white
blood cells such as monocytes, neutrophils and lymphocytes from
the bone marrow into the periphery. This was demonstrated in
mice as well as in a proof-of-mechanism Phase I study in healthy
volunteers. Here, the dose-linear PK profile of the different doses
nicely correlated with a dose-dependent mobilization effect that
peaked approximately 12 h after intravenous (i.v.) administration
of NOX-A12. In spite of the dose linearity, a saturation of the effect
could be observed at the second highest dose [35].
The complex interactions between hematopoietic cells and the
local bone marrow microenvironment support growth, develop-
ment and function, and this can also be attributed to cancer cells.
By modulating the microenvironment of the tumor in the bone
marrow niche through inhibition of SDF-1 with NOX-A12, tumor
cells can be mobilized to peripheral blood where they can be
targeted more effectively by chemotherapy and biologics. In addi-
tion, SDF-1 itself is a survival factor for some leukemic cells, thus
reducing viability if the tumor does not receive SDF-1 and other
signals from this niche [79,80]. In this context, NOX-A12 can be
differentiated from CXCR4-blocking agents because it neutralizes
SDF-1 action on its two receptors: CXCR4 and CXCR7, the latter
being responsible for growth, migration and metastasis in some
types of cancer [81,82]. Functional proof for effects on cancer cell
distribution has been obtained by inhibiting homing of human
chronic lymphocytic leukemia (CLL) cells to bone marrow in mice
[37]. Further preclinical data also showed that NOX-A12 in com-
bination with the proteasome inhibitor bortezomib significantly
reduced tumor load of luciferase-transfected human multiple
myeloma cells in mice. Additionally, homing of a multiple mye-
loma (MM) cell line to bone marrow niches in mouse was reduced
in the presence of NOX-A12. Homing to bone marrow is an
indicator for bone marrow metastasis, which leads to inhibition
of normal hematopoiesis in MM [36].
Currently, NOX-A12 is being tested in two parallel Phase IIa
trials. In the first trial NOX-A12 is combined with bendamustine
and rituximab (BR) for the treatment of relapsed/refractory CLL
patients. In the second trial the combination of NOX-A12 with
bortezomib and dexamethasone (VD) in relapsed/refractory MM
patients is being investigated. In an analysis of pilot groups that
received NOX-A12 alone before the combination with background
therapy, the mobilization of malignant cells (CLL and plasma cells,respectively) was maintained over 72 h. After the six months of
combination therapy, response rates in both trials compared
favorably with historical controls (increased overall response rate
and improved quality of responses) with virtual absence of addi-
tional toxicity on top of the standard treatment [42,43,83–85].
NOX-E36: emapticap pegol
The MCP-1-neutralizing Spiegelmer NOX-E36 has completed a
single ascending dose study (Phase I), a four-week multiple ascend-
ing dose study (Phase Ib) including type 2 diabetes patients and a
single dose study in renally impaired patients for the investigation
of potentially altered elimination kinetics. In all clinical studies,
NOX-E36 was safe and well tolerated. The drug showed a dose-
linear plasma exposition, and a dose-dependent reduction of
peripheral blood monocytes carrying the MCP-1 receptor CCR2
was observed. This demonstrates that the drug effectively antag-
onizes the CCL2/CCR2 axis in humans [24].
NOX-E36 was recently studied in a double-blind, randomized,
placebo-controlled Phase IIa study for the treatment of diabetic
nephropathy. Seventy-five type 2 diabetes patients with albumin-
uria were treated on stable blockade of the renin angiotensin
system (RAS-blockade using either an inhibitor of angiotensin-
converting enzyme or an angiotensin receptor blocker) and anti-
diabetic treatment over a period of three months and followed for
a further three months [86]. In this study, NOX-E36 reduced
urinary albumin excretion, a measure of nephropathy, and also
reduced glycosylated hemoglobin (HBA1c), a measure of glycemic
control. Importantly, these effects were independent of blood
pressure or eGFR, such as those induced by RAS blockade, and
the observations were maintained even after cessation of NOX-E36
treatment, suggesting that the Spiegelmer interferes with the
underlying pathophysiology of diabetic nephropathy. It is aimed
to introduce NOX-E36 as the first agent to modify the course of
diabetic nephropathy, to delay end-stage renal disease and ulti-
mately to save patients from the need for renal-replacement
therapy (transplantation, hemodialysis), at least for some time
[25,87]. Moreover, by improving the kidney function, NOX-E36
could thus reduce the risk of cardiovascular events [88].
NOX-H94: lexaptepid pegol
At first, the hepcidin-neutralizing Spiegelmer NOX-H94 completed
a combined single and multiple dose study. The drug was generally
safe and well tolerated. PK analyses showed a dose-linear systemic
exposure correlated with dose-dependent increases in iron param-
eters [45]. NOX-H94 was then tested in a randomized, double-blind,
placebo-controlled PK/PD study in 24 healthy young men receiving
a low-dose lipopolysaccharide (LPS) infusion and a single dose of
NOX-H94 or placebo. LPS induced a transient drop in serum iron in
the placebo group, probably via interleukin (IL)-6 production, that
leads to hepcidin overexpression. Conversely, in the LPS plus NOX-
H94 group, where hepcidin is blocked, an increase in serum iron was
observed, which was significant at the pre-defined endpoint: 9 h
after LPS injection [46]. NOX-H94 is currently being tested in
patients with anemia of chronic disease. In a pilot study NOX-
H94 has demonstrated efficacy in a subset of anemic cancer patients
with functional iron deficiency by positively influencing pharma-
codynamic (PD) parameters of iron metabolism and erythropoiesis
as well as hemoglobin levels [89]. The Phase IIa studies are beingwww.drugdiscoverytoday.com 153
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(ESA)-hyporesponsive anemia [90].
Concluding remarks
The concept of including chiral principles in the evolutionary
screening process SELEX has progressed from first proof-of-con-
cept reports to a technology that can deliver highly selective,
nonimmunogenic, safe and well-tolerated new chemical entities
with high plasma stability and a predictable PK profile. The
preparation of the mirror-image target required for the screening
process is an important and sometimes challenging step, particu-
larly when targets are chemically or biologically more complex.
Whereas smaller peptide targets that are more easily accessible
were preferred in the early days of Spiegelmer discovery and
development, now encouraging results have been achieved with154 www.drugdiscoverytoday.comlarger polypeptides, protein fragments or even domains of full-
length proteins.
So far, one stabilized D-aptamer (Macugen1) is approved for
local treatment of the eye. Three other D-aptamers are currently
being evaluated in Phase II and III trials (two of which are also for
local ocular treatment). On the Spiegelmer side, three systemically
acting drug candidates are in Phase II studies in various indica-
tions. So far, Spiegelmers have demonstrated a good safety profile,
and all clinical candidates have demonstrated inhibition of their
respective target in healthy volunteers as well as patients. Most
importantly, the accomplished proof-of-concept for emapticap
pegol in a double-blind placebo-controlled Phase IIa study and
promising signs of efficacy with olaptesed pegol as well as lex-
aptepid pegol in patients are encouraging and justify further
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